Polypeptides including modified constant regions
AssigneeCambridge University Technical Services Limited
InventorsKathryn Lesley ARMOUR, Michael Ronald Clark
Life of this patent
Estimating the term…
Abstract
Disclosed are processes for producing a variant polypeptide (e.g. antibodies) having increased binding affinity for an FcγR, which processes comprise modifying the polypeptides by substitution of the amino acid at position 268 of a human IgG CH2 region for a non-native polar or charged amino acid e.g. Gln, Asn, Glu, or Asp. also provided are corresponding polypeptides, nucleic acids, and methods of use of the same e.g. in improved lytic therapies.
Claims33
An isolated IgG antibody comprising a CH2 region, wherein said CH2 region is human but for Asp at position 268 according to the EU numbering system.
An isolated IgG antibody comprising a CH2 region which contains Asp at position 268 according to the EU numbering system.
An isolated human IgG antibody comprising Asp at position 268 according to the EU numbering system.
A fusion protein comprising a binding molecule, said binding molecule comprising a binding domain capable of binding a target molecule and an effector domain comprising a variant CH2 polypeptide in which the amino acid at position 268 of the variant polypeptide is D (Asp).
An isolated IgG antibody comprising a CH2 region, wherein said CH2 region is human but for Asp at position 268 according to the EU numbering system, said isolated IgG antibody having increased binding affinity for FcγRIII as compared to the same IgG antibody which does not contain Asp at position 268.
An isolated IgG antibody comprising a CH2 region which contains Asp at position 268 according to the EU numbering system, said isolated IgG antibody having increased binding affinity for FcγRIII as compared to the same IgG antibody which does not contain Asp at position 268.
An isolated human IgG antibody comprising Asp at position 268 according to the EU numbering system, said isolated human IgG antibody having increased binding affinity for FcγRIII as compared to the same IgG antibody which does not contain Asp at position 268.
Dependencies are inferred from the claim text.